MedEquities Realty Trust (MRT) Upgraded by ValuEngine to Sell

ValuEngine upgraded shares of MedEquities Realty Trust (NYSE:MRT) from a strong sell rating to a sell rating in a research note issued to investors on Saturday morning.

A number of other brokerages have also recently commented on MRT. Citigroup raised shares of MedEquities Realty Trust from a sell rating to a neutral rating and set a $9.00 target price on the stock in a report on Monday, November 12th. JMP Securities set a $12.00 target price on shares of MedEquities Realty Trust and gave the company a buy rating in a report on Tuesday, October 23rd. Zacks Investment Research raised shares of MedEquities Realty Trust from a strong sell rating to a hold rating in a report on Wednesday, October 10th. B. Riley cut their target price on shares of MedEquities Realty Trust from $12.00 to $11.00 and set a buy rating on the stock in a report on Tuesday, November 13th. Finally, Cantor Fitzgerald reaffirmed a neutral rating and issued a $10.00 target price (down from $12.00) on shares of MedEquities Realty Trust in a report on Friday, September 28th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. MedEquities Realty Trust has an average rating of Hold and a consensus target price of $11.00.

Shares of MedEquities Realty Trust stock opened at $7.06 on Friday. The firm has a market capitalization of $224.95 million, a PE ratio of 6.25 and a beta of 0.56. MedEquities Realty Trust has a 12 month low of $6.54 and a 12 month high of $12.00.

MedEquities Realty Trust (NYSE:MRT) last announced its earnings results on Monday, November 12th. The financial services provider reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.25). The business had revenue of $9.68 million during the quarter, compared to analyst estimates of $17.72 million. MedEquities Realty Trust had a net margin of 19.98% and a return on equity of 3.39%. Analysts predict that MedEquities Realty Trust will post 0.8 earnings per share for the current fiscal year.

In related news, Director Bluemountain Capital Managemen sold 3,955 shares of MedEquities Realty Trust stock in a transaction on Friday, October 5th. The shares were sold at an average price of $9.13, for a total value of $36,109.15. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last quarter, insiders sold 456,287 shares of company stock worth $3,715,805. 3.00% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc grew its position in MedEquities Realty Trust by 7.0% in the 3rd quarter. Vanguard Group Inc now owns 3,151,744 shares of the financial services provider’s stock valued at $30,635,000 after buying an additional 205,635 shares during the last quarter. Vanguard Group Inc. grew its position in MedEquities Realty Trust by 7.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,151,744 shares of the financial services provider’s stock valued at $30,635,000 after buying an additional 205,635 shares during the last quarter. AQR Capital Management LLC grew its position in MedEquities Realty Trust by 94.3% in the 3rd quarter. AQR Capital Management LLC now owns 132,341 shares of the financial services provider’s stock valued at $1,286,000 after buying an additional 64,221 shares during the last quarter. MetLife Investment Advisors LLC grew its position in MedEquities Realty Trust by 65.1% in the 3rd quarter. MetLife Investment Advisors LLC now owns 17,683 shares of the financial services provider’s stock valued at $172,000 after buying an additional 6,974 shares during the last quarter. Finally, Putnam Investments LLC grew its position in MedEquities Realty Trust by 664.8% in the 3rd quarter. Putnam Investments LLC now owns 178,190 shares of the financial services provider’s stock valued at $1,732,000 after buying an additional 154,890 shares during the last quarter. Hedge funds and other institutional investors own 92.13% of the company’s stock.

About MedEquities Realty Trust

MedEquities Realty Trust (NYSE: MRT) is a self-managed and self-administered real estate investment trust that invests in a diversified mix of healthcare properties and healthcare-related real estate debt investments. The Company's management team has extensive industry experience in acquiring, owning, developing, financing, operating, leasing and monetizing many types of healthcare properties and portfolios.

Recommended Story: Dividend Aristocrat Index

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for MedEquities Realty Trust (NYSE:MRT)

Receive News & Ratings for MedEquities Realty Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedEquities Realty Trust and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply